About Us

It is primarily set up to develop and commercialize non-invasive, protein-based diagnostic applications.

First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in A*STAR’s Institute of Molecular and Cell Biology (IMCB) by BioCheetah’s Scientific Founder (Prof. Jean Paul Thiery) and the co-Founder/Chief Executive Officer (Dr. Kian-Chung Lee).

Read More
Bio Cheetah
Products

An algorithm has been created to enable a more accurate and conclusive testing result

Bio Cheetah

ELISA IVD Test Kit

For the detection of bladder cancer non-invasively in hematuria and recurrent bladder cancer patients.

Bio Cheetah

Point-of-Care Testing Kit

Our Point-of-Care Testing (POCT) kit is currently under development that caters to General Practitioners (GPs) and polyclinics for rapid qualitative analysis of the bladder cancer biomarkers.

Bio Cheetah
ANNOUNCEMENT

News Release

Promising clinical trials aims to detect bladder cancer via a quick liquid biopsy test

Bladder cancer is the 10th most common form of cancer worldwide in both genders and…

Read More

BioCheetah clinched two awards at the Asian Entrepreneurship Awards 2019

The Asian Entrepreneurship Award (AEA) 2019 was held from October 30 to November 1 in…

Read More